Abstract
Adiponectin (ADPN) is an adipokine with significant anti-inflammatory, insulin-sensitizing and anti-atherogenic properties, which is generally associated with a beneficial cardiometabolic profile. Paradoxically, end-stage renal disease (ESRD) is characterized by markedly increased plasma ADPN levels and increased cardiovascular risk. In spite of the cardioprotective properties attributed to adiponectin, cardiovascular complications remain the main cause of mortality in the ESRD population. Furthermore, these patients have enhanced chronic inflammation, increased insulin resistance and persistent protein-energy wasting. Studies of the impact of ADPN on clinical outcomes among ESRD patients have so far yielded contradictory results. This review article summarizes the current knowledge on ADPN functions and explores the role of ADPN in ESRD patients, with specific focus on inflammation, insulin resistance, cardiovascular disease and wasting.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Waki H, Tontonoz P, 2007 Endocrine Functions of Adipose Tissue. Annu Rev Pathol-Mech 2: 31–56.
Shehzad A, Iqbal W, Shehzad O, Lee YS, 2012 Adiponectin: regulation of its production and its role in human diseases. Hormones 11: 8–20.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K, 1996 cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221: 286–289.
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K, 2006 Adiponectin and adiponectin receptors insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784–1792.
Aprahamian TR, Sam F, 2011 Adiponectin in Cardiovascular Inflammation and Obesity. Int J Inflam 2011: 376909–376917.
Nanayakkara PW, Le Poole CY, Fouque D, et al, 2009 Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3–5 chronic kidney disease. Clin Nephrol 72: 21–30.
Zoccali C, Mallamaci F, Tripepi G, et al, 2002 Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134–141.
Kato S, Chmielewski M, Honda H, et al, 2008 Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526–1533.
Pozzoni P, Del Vecchio L, Pontoriero G, Di Filippo S, Locatelli F, 2004 Long-term outcome in hemodialysis: Morbidity and mortality. J Nephrol 17: 87–95.
Guebre-Egziabher F, Drai J, Fouque D, 2007 Adiponectin and chronic kidney disease. J Ren Nutr 17: 9–12.
Kissebah AH, Sonnenberg GE, Myklebust J, et al, 2000 Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97: 14478–14483.
Berg AH, Combs TP, Scherer PE, 2002 ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84–89.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF, 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746–26749.
Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M, 1996 Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120: 803–812.
Tsao TS, Tomas E, Murrey HE, et al, 2003 Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity — Different oligomers activate different signal transduction pathways. J Biol Chem 278: 50810–50817.
Fruebis J, Tsao T-S, Javorschi S, et al, 2001 Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005–2010.
Wang Y, Lam KSL, Chan L, et al, 2006 Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281: 16391–16400.
Bobbert T, Rochlitz H, Wegewitz U, et al, 2005 Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54: 2712–2719.
Yamauchi T, Kamon J, Ito Y, et al, 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769.
Yamauchi T, Kadowaki T, 2013 Adiponectin Receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 17: 185–196.
Yamauchi T, Kamon J, Minokoshi Y, et al, 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–1295.
Yamauchi T, Nio Y, Maki T, et al, 2007 Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13: 332–339.
Kadowaki T, Yamauchi T, 2005 Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451.
Kubota N, Yano W, Kubota T, et al, 2007 Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6: 55–68.
Coope A, Milanski M, Araujo EP, et al, 2008 AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett 582: 1471–1476.
Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR, 2008 Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 89: 1200–1208.
Glintborg D, Frystyk J, Hojlund K, et al, 2008 Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol 68: 165–174.
Arita Y, Kihara S, Ouchi N, et al, 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79–83.
Madsen EL, Rissanen A, Bruun JM, et al, 2008 Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 158: 179–187.
Lara-Castro C, Doud EC, Tapia PC, et al, 2008 Adiponectin Multimers and Metabolic Syndrome Traits: Relative Adiponectin Resistance in African Americans. Obesity 16: 2616–2623.
Zoccali C, Mallamaci F, Panuccio V, et al, 2003 Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 84: 98–102.
Rao M, Lijun L, Tighiouart H, Jaber BL, Pereira BG, 2008 Vaidyanathapuram S. Plasma adiponectin levels and clinical outcomes among hemodialysis patients Nephrol Dial Transplant 23: 2619–2628.
Doumatey AP, Zhou J, Huang H, et al, 2012 Circulating adiponectin is associated with renal function independent of age and serum lipids in west Africans. Int J Nephrol 2012: 1–8.
Lim CC, Teo BW, Tai ES, et al, 2015 Elevated Serum Leptin, Adiponectin and Leptin to Adiponectin Ratio Is Associated with Chronic Kidney Disease in Asian Adults. PLoS ONE 10: e0122009.
Park JT, Yoo T-H, Kim J-K, et al, 2013 Leptin/Adiponectin Ratio Is an Independent Predictor of Mortality in Nondiabetic Peritoneal Dialysis Patients. Perit Dial Int 33: 67–74.
Iwashima Y, Horio T, Kumada M, et al, 2006 Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98: 1603–1608.
Stenvinkel P, Marchlewska A, Pecoits-Filho R, et al, 2004 Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274–281.
Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. 2004 Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kid Dis 43: 1047–1055.
Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW, 2007 Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 22: 17171–17810.
Pham PC, Pham PM, Pham SV, Miller JM, Pham PT, 2007 Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2: 366–373.
Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB, 2006 Adiponectin — a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8: 264–280.
Hotta K, Funahashi T, Arita Y, et al, 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595–1599.
Iwashima Y, Katsuya T, Ishikawa K, et al, 2005 Association of hypoadiponectinemia with smoking habit in men. Hypertension 45:1094–1100.
Dzielińska Z, Januszewicz A, Więcek A, et al, 2003 Decreased plasma concentration of a novel anti-inflammatory protein-adiponectin-in hypertensive men with coronary artery disease. Thromb Res 110: 365–369.
Abdallah E, Waked E, Nabil M, El-Bendary O. 2012 Adiponectin and Cardiovascular Outcomes among Hemodialysis Patients. Kidney Blood Press Res 35: 247–253.
Markaki A, Gkouskou K, Stylianou K, et al, 2014 Relationship between adiposity, adipokines, inflammatory markers and lipid profile in hemodialysis patients. Eur Rev Med Pharmacol Sci 18: 1496–1498.
Tung CW, Hsu YC, Shih YH, Lin CL, 2015 Association of Adiponectin with High-Sensitivity C-Reactive Protein and Clinical Outcomes in Peritoneal Dialysis Patients: A 3.5-Year Foliow-Up Study. PLoS One 16: e0141058.
Adamczak M, Chudek J, Wiecek A, 2009 Adiponectin in patients with chronic kidney disease. Semin Dial 22: 391–395.
Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D, 2005 Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20: 129–134.
Chudek J, Adamczak M, Karkoszka H, et al, 2003 Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 35: 2186–2189.
Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M, 2010 Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients. Am J Nephrol 25: 203–210.
Martinez Cantarin MP, Waldman SA, Doria C, et al, 2013 The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 83: 487–494.
Martinez Cantarin MP, Keith SW, Waldman SA, Falkner B, 2014 Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. Nephrol Dial Transplant 29: 2268–2277.
Yoon MJ, Lee GY, Chung JJ, et al, 2006 Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55: 2562–2570.
DeFronzo RA, Alvestrand A, Smith D, et al, 1981 Insulin resistance in uremia. J Clin Invest 67: 563–568.
Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T, 2005 Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45:275–280.
Shinohara K, Shoji T, Emoto M, et al, 2002 Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13: 1894–1900.
Fouque D, Kalantar-Zadeh K, Kopple J, et al, 2008 A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73: 391–398.
Barazzoni R, 2012 Adipokines, ghrelin and obesity-associated insulin resistance in nondiabetic patients with acute coronary syndrome. Obesity 20: 2348–2353.
Pajvani UB, Hawkins M, Combs TP, et al, 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152–12162.
Liu M, Liu F, 2010 Transcriptional and post-translational regulation of adiponectin. Biochem J 425: 41–52.
Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT, 2006 Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55: 249–259.
Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, 2005 Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16: 1091–1098.
Elokely A, Shoukry A, Ghonemy TA, Atia M, Amr G, 2012 Association of adiponectin with cardiovascular events in diabetic and non-diabetic hemodialysis patients. Saudi J Kidney Dis Transpl 23: 736–742.
Giers K, Niemczyk S, Szamotulska K, et al, 2015 Visceral Adipose Tissue is Associated with Insulin Resistance in Hemodialyzed Patients. Med Sci Monit 21: 557–562.
Lin HV, Kim JY, Pocai A, et al, 2007 Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes 56: 1969–1976.
Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ, 2005 The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 54: 3154–3160.
Chen MB, McAinch AJ, Macaulay SL, et al, 2005 Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 90: 3665–3672.
Welters ID, Bing C, Ding C, Leuwer M, Hall AM, 2014 Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-alpha2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study. BMC Anesthesiol 14: 124–133.
Stenvinkel P, 2006 Inflammation in end-stage renal disease: the hidden enemy. Nephrology 11: 36–41.
Krysiak R, Handzlik-Orlik G, Okopien B, 2012 The Role of Adipokines in Connective Tissue Diseases. Eur J Nutr 51: 513–528.
Aimer G, Saba-Lepek M, Haj-Yahya S, et al, 2011 Globular domain of adiponectin: promising target molecule for detection of atherosclerotic lesions. Biologies 5: 95–105.
Ouchi N, Kihara S, Funahashi T, et al, 2003 Reciprocal association of C-reative protein with adiponectin in blood stream and adipose tissue. Circulation 107: 671–674.
Engeli S, Feldpausch M, Gorzelniak K, et al, 2003 Association between adiponectin and mediators of inflammation in obese women. Diabetes 52: 942–947.
Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. 2003 Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrin & Metab 88: 2714–2718.
Ouchi N, Kihara S, Arita Y, et al, 2001 Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057–1063.
Arita Y, Kihara S, Ouchi N, et al, 2002 Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common post receptor signal in vascular smooth muscle cell. Circulation 18: 2893–2898.
Li CJ, Sun HW, Zhu FL, et al, 2007 Local adiponectin treatment reduces atherosclerotic plaque size in rabbits. J Endocrinol 193: 137–145.
Giannessi D, Maltinti M, Del Ry S, 2007 Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 56: 459–467.
Collins AJ, 2003 Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325: 163–167.
Panichi V, Scatena A, Migliori M, Marchetti V, Paoletti S, Beati S, 2012 Biomarkers of Chronic Inflammatory State in Uremia and Cardiovascular Disease. Int J Inflam 2012: 1–6.
Zoccali, C, Benedetto FA, Mallamaci F, et al, 2000 Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators Cardiovascular Risk Extended Evaluation in Dialysis Patients J Hypertens 18: 1207–1213.
El-Shafey EM, Shalan M, 2014 Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients. Ther Apher Dial 18: 185–192.
Ohashi N, Kato A, Misaki T, et al, 2008 Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 47: 485–491.
Jorsal A, Tarnow L, Frystyk J, et al, 2008 Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 74: 649–654.
Tamadon MR, Heidari M, Dris F, Mardani S, 2015 Correlation of serum adiponectin level with some biochemical and metabolic factors in stable hemodialysis patients. J Parathyr Dis 3: 20–24.
Kistorp C, Faber J, Galatius S, et al, 2005 Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112: 1756–1762.
Kobayashi H, Ouchi N, Kihara S, et al, 2004 Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: 27–31.
Aso Y, Yamamoto R, Wakabayashi S, et al, 2006 Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954–1960.
Iwasa Y, Otsubo S, Ishizuka T, Uchida K, Nitta K, 2008 Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. Nephron Clin Pract 108: 226–232.
Tomizawa A, Hattori Y, Kasai K, Nakano Y, 2008 Adiponectin induces NF-kappa B activiation that leads to suppression of cytokine-induced NF-kappa B activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res 5: 123–127.
Li Y, Xie QH, You HZ, et al, 2012 Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients-a randomized crossover trial. Perit Dial Int 32: 507–515.
Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K, 2009 Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease Am J Clin Nutr 90: 407–414.
Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, 2013 Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 23: 77–90.
Matsumoto S, Hyodo F, Subramanian S, et al, 2008 Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest 118: 1965–1973.
Malgorzewicz S, Aleksandrowicz-Wrona E, Owczarzak A, Debska-Slizien A, Rutkowski B, Lysiak-Szydlowska W, 2010 Adipokines and nutritional status for patients on maintenance hemodialysis. J Ren Nutr 20: 303–308.
Lee S, Park Y, Dellsperger KC, Zhang C, 2011 Exercise training improves endothelial function via adiponectin-dependent and independent pathways in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 301: 306–314.
Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C, 2009 Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 76: 567–575.
Qi Y, Takahashi N, Hileman SM, et al, 2004 Adiponectin acts in the brain to decrease body weight. Nat Med 10: 524–529.
Kaynar K, Kural BV, Ulusoy S, et al, 2014 Is there any interaction of resistin and adiponectin levels with protein-energy wasting among patients with chronic kidney disease. Hemodial Int 18: 153–162.
Ignacy W, Chudek J, Adamczak M, et al, 2005 Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease—a follow-up study. Nephron Clin Pract 101: 18–24.
McDonald SP, Collins JF, Johnson DW, 2003 Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 14: 2894–2901.
Pliakogiannis T, Trpeski L, Taskapan H, et al, 2007 Reverse epidemiology in peritoneal dialysis patients: the Canadian experience and review of the literature. Int Urol Nephrol 39: 281–288.
Pecoits-Filho R, Lindholm B, Stenvinkel P, 2002 The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 17: 28–31.
Shoji T, Shinohara K, Hatsuda S, et al, 2015 Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 54: 330–334.
Tsigalou C, Chalikias G, Kantartzi K, et al, 2013 Differential effect of baseline adiponectin on all-cause mortality in hemodialysis patients depending on initial body mass index. Long-term follow-up data of 4.5 years. J Ren Nutr 23: 45–56.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Markaki, A., Psylinakis, E. & Spyridaki, A. Adiponectin and end-stage renal disease. Hormones 15, 345–354 (2016). https://doi.org/10.14310/horm.2002.1698
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1698